Authors:
Nasu, Y
Bangma, CH
Hull, GW
Yang, G
Wang, J
Shimura, S
McCurdy, MA
Ebara, S
Lee, HM
Timme, TL
Thompson, TC
Citation: Y. Nasu et al., Combination gene therapy with adenoviral vector-mediated HSV-tk plus GCV and IL-12 in an orthotopic mouse model for prostate cancer, PROSTATE C, 4(1), 2001, pp. 44-55
Authors:
Miles, BJ
Shalev, M
Aguilar-Cordova, E
Timme, TL
Lee, HM
Yang, G
Adler, HL
Kernen, K
Pramudji, CK
Satoh, T
Gdor, Y
Ren, CZ
Ayala, G
Wheeler, TM
Butler, EB
Kadmon, D
Thompson, TC
Citation: Bj. Miles et al., Prostate-specific antigen response and systemic T cell activation after insitu gene therapy in prostate cancer patients failing radiotherapy, HUM GENE TH, 12(16), 2001, pp. 1955-1967
Authors:
Shaker, MR
Yang, G
Timme, TL
Park, SH
Kadmon, D
Ren, CZ
Ji, XR
Lee, HM
Sehgal, I
Anzano, M
Sporn, MB
Thompson, TC
Citation: Mr. Shaker et al., Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression, CLIN EXP M, 18(5), 2001, pp. 429-438
Authors:
Li, LK
Yang, G
Ebara, S
Satoh, T
Nasu, Y
Timme, TL
Ren, CZ
Wang, JX
Tahir, SA
Thompson, TC
Citation: Lk. Li et al., Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells, CANCER RES, 61(11), 2001, pp. 4386-4392
Authors:
Tahir, SA
Yang, G
Ebara, S
Timme, TL
Satoh, T
Li, LK
Goltsov, A
Ittmann, M
Morrisett, JD
Thompson, TC
Citation: Sa. Tahir et al., Secreted caveolin-1 stimulates cell survival/clonal growth and contributesto metastasis in androgen-insensitive prostate cancer, CANCER RES, 61(10), 2001, pp. 3882-3885
Authors:
Hull, GW
McCurdy, MA
Nasu, Y
Bangma, CH
Yuang, G
Shimura, S
Lee, HM
Wang, JX
Albani, J
Ebara, S
Sato, T
Timme, TL
Thompson, TC
Citation: Gw. Hull et al., Prostate cancer gene therapy: Comparison of adenovirus-mediated expressionof interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines, CLIN CANC R, 6(10), 2000, pp. 4101-4109
Authors:
Thompson, TC
Timme, TL
Park, SH
Yang, G
Ren, CZ
Citation: Tc. Thompson et al., Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease, PROSTATE, 43(4), 2000, pp. 248-254
Citation: Hm. Lee et al., Resistance to lysis by cytotoxic T cells: A dominant effect in metastatic mouse prostate cancer cells, CANCER RES, 60(7), 2000, pp. 1927-1933
Citation: Tc. Thompson et al., Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer, APOPTOSIS, 4(4), 1999, pp. 233-237
Authors:
Herman, JR
Adler, HL
Aguilar-Cordova, E
Rojas-Martinez, A
Woo, S
Timme, TL
Wheeler, TM
Thompson, TC
Scardino, PT
Citation: Jr. Herman et al., In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial, HUM GENE TH, 10(7), 1999, pp. 1239-1249
Authors:
Nasu, Y
Bangma, CH
Hull, GW
Lee, HM
Wang, J
McCurdy, MA
Shimura, S
Yang, G
Timme, TL
Thompson, TC
Citation: Y. Nasu et al., Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in anorthotopic model, GENE THER, 6(3), 1999, pp. 338-349
Authors:
Hall, SJ
Mutchnik, SE
Yang, G
Timme, TL
Nasu, Y
Bangma, CH
Woo, SLC
Shaker, M
Thompson, TC
Citation: Sj. Hall et al., Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer, CANC GENE T, 6(1), 1999, pp. 54-63
Citation: Hl. Adler et al., Elevated levels of circulating interleukin-6 and transforming growth factor-beta 1 in patients with metastatic prostatic carcinoma, J UROL, 161(1), 1999, pp. 182-187